mirvetuximab soravtansine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
chimeric origin 5691 1453084-37-1

Description:

MoleculeDescription

Molfile

Synonyms:

  • mirvetuximab soravtansine
  • mirvetuximab soravtansine-gynx
  • elahere
  • IMGN853
Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against folate receptor alpha (FRalpha). The small molecule, DM4, is a microtubule inhibitor attached to the antibody via a cleavable linker. Upon binding to FRalpha, mirvetuximab soravtansine-gynx is internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death.
  • Molecular weight:
  • Formula: C2H7N(C41H56ClN3O14S3)n
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 14, 2022 FDA IMMUNOGEN INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
FRalpha positive platinum-resistant epithelial ovarian cancer indication 254849005
FRalpha positive platinum-resistant fallopian tube cancer indication 363444001 DOID:1964
FRalpha positive platinum-resistant primary peritoneal cancer indication 363492001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Folate receptor alpha Membrane receptor BINDING AGENT Kd 10.12 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEMBL3545132 ChEMBL_ID
C000607289 MESH_SUPPLEMENTAL_RECORD_UI
12250 IUPHAR_LIGAND_ID
DB12489 DRUGBANK_ID
019225 NDDF
4041843 VANDF
4041844 VANDF
C4288736 UMLSCUI
10176 INN_ID
D10954 KEGG_DRUG
91810695 PUBCHEM_CID
2621548 RXNORM
363141 MMSL
41058 MMSL
d09944 MMSL
98DE7VN88D UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ELAHERE HUMAN PRESCRIPTION DRUG LABEL 1 72903-853 INJECTION, SOLUTION 100 mg INTRAVENOUS BLA 33 sections